Yale Cancer Center researchers have identified a gene in melanoma that can dramatically affect the growth of the disease. The findings, published in the journal Cell Reports, provide new insight into how melanoma grows and identifies a new target for treatment of melanoma and other cancers.
MRV Research
Treatment and follow-up of cutaneous melanoma
By Reinhard Dummer, et al.: In order to guide treatment decisions and follow-up of melanoma patients, guidelines for the management of melanoma in Switzerland were inaugurated in 2001 and revised in 2006 and, most recently, in 2016. Recent data from randomised trials necessitated modifications of the treatment and follow-up recommendations.
Melanoma Patients Treated With Dabrafenib, Trametinib Have Overall Survival Rates of More Than 2 Years
Patients with BRAF V600E-mutant metastatic melanoma who were treated with a combination of the mitogen-activated protein kinase (MAPK) inhibitors dabrafenib and trametinib demonstrated significant improvement in overall and progression-free survival.1
Cancer Immunotherapy May Improve with Identification of New Mutations
The primary goal of cancer immunotherapy is to stimulate the human immune system to identify and destroy developing tumors. However, forcing immune cells to recognize tissues as foreign is proving to be much more difficult than researchers had hoped. However, a team of scientists at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin has identified immunogenic mutations in T cell receptors that occur naturally in human melanoma.